At the end of the in vivo experiment, the tumor sizes of the CD90+HepG2/DC-CTL group were the smallest among the four groups and the difference became significant at 7 weeks after injection (Figures 5(b) and 5(c)). The gene discussed is THY1; the disease is neoplasm.